Implications of NAD metabolism in pathophysiology and therapeutics for neurodegenerative diseases

References

• Procaccini C, Santopaolo M, Faicchia D, Colamatteo A, Formisano L, de Candia P, et al. Role of metabolism in neurodegenerative disorders. Metabolism. 2016;65(9):1376–90.
   PubMed Web of Science ®Google Scholar
• Karbowski M, Neutzner A. Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol. 2012;123(2):157–71.
   PubMed Web of Science ®Google Scholar
• Harman D. The aging process. Proc Natl Acad Sci U S A. 1981;78(11):7124–8.
   PubMed Web of Science ®Google Scholar
• Sun N, Youle RJ, Finkel T. The mitochondrial basis of aging. Mol Cell. 2016;61(5):654–66.
   PubMed Web of Science ®Google Scholar
• Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest. 2013;123(3):951–7.
   PubMed Web of Science ®Google Scholar
• Harman D. The free radical theory of aging. Antioxid Redox Signal. 2003;5(5):557–61.
   PubMed Web of Science ®Google Scholar
• Burkle A. DNA repair and PARP in aging. Free Radic Res. 2006;40(12):1295–302.
   PubMed Web of Science ®Google Scholar
• Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009;7(1):65–74.
   PubMed Web of Science ®Google Scholar
• Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787–95.
   PubMed Web of Science ®Google Scholar
• Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene. 2013;532(1):18–23.
   PubMed Web of Science ®Google Scholar
• Clarke JR, Lyra ESNM, Figueiredo CP, Frozza RL, Ledo JH, Beckman D, et al. Alzheimer-associated abeta oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med. 2015;7(2):190–210.
   PubMed Web of Science ®Google Scholar
• Kennedy MA, Moffat TC, Gable K, Ganesan S, Niewola-Staszkowska K, Johnston A, et al. A signaling lipid associated with Alzheimer's disease promotes mitochondrial dysfunction. Sci Rep. 2016;6:19332.
   PubMedGoogle Scholar
• Dunn L, Allen GF, Mamais A, Ling H, Li A, Duberley KE, et al. Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease. Neurobiol Aging. 2014;35(5):1111–5.
   PubMed Web of Science ®Google Scholar
• Knight AL, Yan X, Hamamichi S, Ajjuri RR, Mazzulli JR, Zhang MW, et al. The glycolytic enzyme, GPI, is a functionally conserved modifier of dopaminergic neurodegeneration in Parkinson's models. Cell Metab. 2014;20(1):145–57.
   PubMed Web of Science ®Google Scholar
• Yaku K, Okabe K, Nakagawa T. NAD metabolism: implications in aging and longevity. Ageing Res Rev. 2018;47:1–17.
   PubMed Web of Science ®Google Scholar
• Wang J, He Z. NAD and axon degeneration: from the wlds gene to neurochemistry. Cell Adh Migr. 2009;3(1):77–87.
   PubMed Web of Science ®Google Scholar
• Salvadores N, Sanhueza M, Manque P, Court FA. Axonal degeneration during aging and its functional role in neurodegenerative disorders. Front Neurosci. 2017;11:451.
   PubMed Web of Science ®Google Scholar
• Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754–63.
   PubMed Web of Science ®Google Scholar
• Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem. 2005;280(43):36334–41.
   PubMed Web of Science ®Google Scholar
• Canto C, Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol. 2009;20(2):98–105.
   PubMed Web of Science ®Google Scholar
• Salvatori I, Valle C, Ferri A, Carri MT. SIRT3 and mitochondrial metabolism in neurodegenerative diseases. Neurochem Int. 2017;109:184–92.
   PubMed Web of Science ®Google Scholar
• Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S. Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur J Neurosci. 1989;1(1):27–33.
   PubMed Web of Science ®Google Scholar
• Lyon MF, Ogunkolade BW, Brown MC, Atherton DJ, Perry VH. A gene affecting Wallerian nerve degeneration maps distally on mouse chromosome 4. Proc Natl Acad Sci U S A. 1993;90(20):9717–20.
   PubMed Web of Science ®Google Scholar
• Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/nmnat chimeric gene. Nat Neurosci. 2001;4(12):1199–206.
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Vohra BP, Baloh RH, Milbrandt J. Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J Neurosci. 2009;29(20):6526–34.
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci. 2006;26(33):8484–91.
   PubMed Web of Science ®Google Scholar
• Press C, Milbrandt J. Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. J Neurosci. 2008;28(19):4861–71.
   PubMed Web of Science ®Google Scholar
• Yahata N, Yuasa S, Araki T. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci. 2009;29(19):6276–84.
   PubMed Web of Science ®Google Scholar
• Verghese PB, Sasaki Y, Yang D, Stewart F, Sabar F, Finn MB, et al. Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death. Proc Natl Acad Sci U S A. 2011;108(47):19054–9.
   PubMed Web of Science ®Google Scholar
• Galindo R, Banks Greenberg M, Araki T, Sasaki Y, Mehta N, Milbrandt J, Holtzman DM. NMNAT3 is protective against the effects of neonatal cerebral hypoxia-ischemia. Ann Clin Transl Neurol. 2017;4(10):722–38.
   PubMed Web of Science ®Google Scholar
• Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 2010;8(1):e1000300.
   PubMed Web of Science ®Google Scholar
• Gilley J, Mayer PR, Yu G, Coleman MP. Low levels of NMNAT2 compromise axon development and survival. Hum Mol Genet. 2019;28(3):448–58.
   PubMed Web of Science ®Google Scholar
• Gilley J, Adalbert R, Yu G, Coleman MP. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. J Neurosci. 2013;33(33):13410–24.
   PubMed Web of Science ®Google Scholar
• Milde S, Gilley J, Coleman MP. Subcellular localization determines the stability and axon protective capacity of axon survival factor Nmnat2. PLoS Biol. 2013;11(4):e1001539.
   PubMed Web of Science ®Google Scholar
• Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305(5686):1010–3.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, He Z. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol. 2005;170(3):349–55.
   PubMed Web of Science ®Google Scholar
• Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, et al. Dsarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;337(6093):481–4.
   PubMed Web of Science ®Google Scholar
• Gilley J, Orsomando G, Nascimento-Ferreira I, Coleman MP. Absence of SARM1 rescues development and survival of NMNAT2-deficient axons. Cell Rep. 2015;10(12):1974–81.
   PubMed Web of Science ®Google Scholar
• Gilley J, Ribchester RR, Coleman MP. Sarm1 deletion, but Not Wld(S), confers lifelong rescue in a mouse model of severe axonopathy. Cell Rep. 2017;21(1):10–6.
   PubMed Web of Science ®Google Scholar
• Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci. 2013;33(33):13569–80.
   PubMed Web of Science ®Google Scholar
• Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD(+) destruction. Science. 2015;348(6233):453–7.
   PubMed Web of Science ®Google Scholar
• Summers DW, Gibson DA, DiAntonio A, Milbrandt J. SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation. Proc Natl Acad Sci U S A. 2016;113(41):E6271–E80.
   PubMed Web of Science ®Google Scholar
• Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/interleukin-1 receptor domain possesses intrinsic NAD(+) cleavage activity that promotes pathological axonal degeneration. Neuron. 2017;93(6):1334–43 e5.
   PubMed Web of Science ®Google Scholar
• Malapati H, Millen SM, JB W. The axon degeneration gene SARM1 is evolutionarily distinct from other TIR domain-containing proteins. Mol Genet Genomics. 2017;292(4):909–22.
   PubMed Web of Science ®Google Scholar
• Summers DW, DiAntonio A, Milbrandt J. Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons. J Neurosci. 2014;34(28):9338–50.
   PubMed Web of Science ®Google Scholar
• Yang J, Wu Z, Renier N, Simon DJ, Uryu K, Park DS, et al. Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell. 2015;160(1–2):161–76.
   PubMed Web of Science ®Google Scholar
• Murata H, Khine CC, Nishikawa A, Yamamoto KI, Kinoshita R. And sakaguchi M, c-Jun N-terminal kinase (JNK)-mediated phosphorylation of SARM1 regulates NAD(+) cleavage activity to inhibit mitochondrial respiration. J Biol Chem. 2018;293(49):18933–43.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang S, Liu T, Wang H, Liu K, Wang Q, Zeng W. Sarm1/Myd88-5 regulates neuronal intrinsic immune response to traumatic axonal injuries. Cell Rep. 2018;23(3):716–24.
   PubMed Web of Science ®Google Scholar
• Vaur P, Brugg B, Mericskay M, Li Z, Schmidt MS, Vivien D, et al. Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration. FASEB J. 2017;31(12):5440–52.
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Nascimento-Ferreira I, Orsomando G, Mori V, Gilley J, Brown R, et al. A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. Cell Death Differ. 2015;22(5):731–42.
   PubMed Web of Science ®Google Scholar
• Di Stefano M, Loreto A, Orsomando G, Mori V, Zamporlini F, Hulse RP, et al. NMN deamidase delays wallerian degeneration and rescues axonal defects caused by NMNAT2 deficiency In vivo. Curr Biol. 2017;27(6):784–94.
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Nakagawa T, Mao X, DiAntonio A, Milbrandt J. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD(+) depletion. eLife. 2016;5:e19749.
   PubMed Web of Science ®Google Scholar
• Liu HW, Smith CB, Schmidt MS, Cambronne XA, Cohen MS, Migaud ME, et al. Pharmacological bypass of NAD(+) salvage pathway protects neurons from chemotherapy-induced degeneration. Proc Natl Acad Sci USA. 2018;115(42):10654–10659.
   PubMed Web of Science ®Google Scholar
• England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151–61.
   PubMed Web of Science ®Google Scholar
• Wang MS, Davis AA, Culver DG, Glass JD. Wlds mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol. 2002;52(4):442–7.
   PubMed Web of Science ®Google Scholar
• Turkiew E, Falconer D, Reed N, Hoke A. Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy. J Peripher Nerv Syst. 2017;22(3):162–71.
   PubMed Web of Science ®Google Scholar
• Trammell SA, Weidemann BJ, Chadda A, Yorek MS, Holmes A, Coppey LJ, et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci Rep. 2016;6:26933.
   PubMed Web of Science ®Google Scholar
• LoCoco PM, Risinger AL, Smith HR, Chavera TS, Berg KA, Clarke WP. Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy. eLife. 2017;6:e29626.
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Hackett AR, Kim S, Strickland A, Milbrandt J. Dysregulation of NAD(+) metabolism induces a Schwann cell dedifferentiation program. J Neurosci. 2018;38(29):6546–62.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Q, Bao R, Zhang N, Wang Y, Polo-Parada L, et al. Deletion of Nampt in projection neurons of adult mice leads to motor dysfunction, neurodegeneration, and death. Cell Rep. 2017;20(9):2184–200.
   PubMed Web of Science ®Google Scholar
• Ivanisevic J, Stauch KL, Petrascheck M, Benton HP, Epstein AA, Fang M, et al. Metabolic drift in the aging brain. Aging (Albany NY). 2016;8(5):1000–20.
   PubMedGoogle Scholar
• Zhu XH, Lu M, Lee BY, Ugurbil K, Chen W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A. 2015;112(9):2876–81.
   PubMed Web of Science ®Google Scholar
• Liu LY, Wang F, Zhang XY, Huang P, Lu YB, Wei EQ, Zhang WP. Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases. PLoS One. 2012;7(10):e44933.
   PubMed Web of Science ®Google Scholar
• Clement J, Wong M, Poljak A, Sachdev P, Braidy N. The Plasma NAD(+) metabolome Is dysregulated in “normal” aging. Rejuvenation Res. 2019;22(2):121–130.
   PubMed Web of Science ®Google Scholar
• Stein LR, Wozniak DF, Dearborn JT, Kubota S, Apte RS, Izumi Y, et al. Expression of Nampt in hippocampal and cortical excitatory neurons is critical for cognitive function. J Neurosci. 2014;34(17):5800–15.
   PubMed Web of Science ®Google Scholar
• Thomas T, Thomas G, McLendon C, Sutton T. And Mullan M, beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996;380(6570):168–71.
   PubMed Web of Science ®Google Scholar
• Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A. 2010;107(43):18670–5.
   PubMed Web of Science ®Google Scholar
• Sorrentino V, Romani M, Mouchiroud L, Beck JS, Zhang H, D'Amico D, et al. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity. Nature. 2017;552(7684):187–93.
   PubMed Web of Science ®Google Scholar
• Ghosh D, Levault KR, Brewer GJ. Relative importance of redox buffers GSH and NAD(P)H in age-related neurodegeneration and Alzheimer disease-like mouse neurons. Aging Cell. 2014;13(4):631–40.
   PubMed Web of Science ®Google Scholar
• Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging. 2013;34(6):1581–8.
   PubMed Web of Science ®Google Scholar
• Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, et al. NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018;115(8):E1876–E85.
   PubMed Web of Science ®Google Scholar
• Long AN, Owens K, Schlappal AE, Kristian T, Fishman PS, Schuh RA. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model. BMC Neurol. 2015;15:19.
   PubMed Web of Science ®Google Scholar
• Yao Z, Yang W, Gao Z, Jia P. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci Lett. 2017;647:133–40.
   PubMed Web of Science ®Google Scholar
• Wang X, Hu X, Yang Y, Takata T, Sakurai T. Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 2016;1643:1–9.
   PubMed Web of Science ®Google Scholar
• Ljungberg MC, Ali YO, Zhu J, Wu CS, Oka K, Zhai RG, Lu HC. CREB-activity and nmnat2 transcription are down-regulated prior to neurodegeneration, while NMNAT2 over-expression is neuroprotective, in a mouse model of human tauopathy. Hum Mol Genet. 2012;21(2):251–67.
   PubMed Web of Science ®Google Scholar
• Cheng XS, Zhao KP, Jiang X, Du LL, Li XH, Ma ZW, et al. Nmnat2 attenuates Tau phosphorylation through activation of PP2A. J Alzheimers Dis. 2013;36(1):185–95.
   PubMed Web of Science ®Google Scholar
• Musiek ES, Xiong DD, Patel T, Sasaki Y, Wang Y, Bauer AQ, et al. Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy. Ann Clin Transl Neurol. 2016;3(6):434–42.
   PubMed Web of Science ®Google Scholar
• Rossi F, Geiszler PC, Meng W, Barron MR, Prior M, Herd-Smith A, et al. NAD-biosynthetic enzyme NMNAT1 reduces early behavioral impairment in the htau mouse model of tauopathy. Behav Brain Res. 2018;339:140–52.
   PubMed Web of Science ®Google Scholar
• Liu F, Arias-Vasquez A, Sleegers K, Aulchenko YS, Kayser M, Sanchez-Juan P, et al. A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet. 2007;81(1):17–31.
   PubMed Web of Science ®Google Scholar
• Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, Bellen HJ. NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature. 2008;452(7189):887–91.
   PubMed Web of Science ®Google Scholar
• Ali YO, Ruan K, Zhai RG. NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet. 2012;21(2):237–50.
   PubMed Web of Science ®Google Scholar
• Ali YO, Allen HM, Yu L, Li-Kroeger D, Bakhshizadehmahmoudi D, Hatcher A, et al. NMNAT2:HSP90 complex mediates proteostasis in proteinopathies. PLoS Biol. 2016;14(6):e1002472.
   PubMed Web of Science ®Google Scholar
• Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016;139(Suppl 1):216–31.
   PubMed Web of Science ®Google Scholar
• Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. 2010;2(52):52ra73.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Loh SH, Martins LM. Enhancing NAD(+) salvage metabolism is neuroprotective in a PINK1 model of Parkinson's disease. Biol Open. 2017;6(2):141–7.
   PubMed Web of Science ®Google Scholar
• Schondorf DC, Ivanyuk D, Baden P, Sanchez-Martinez A, De Cicco S, Yu C, et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and Fly models of Parkinson's disease. Cell Rep. 2018;23(10):2976–88.
   PubMed Web of Science ®Google Scholar
• Schwab AJ, Sison SL, Meade MR, Broniowska KA, Corbett JA, Ebert AD. Decreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons. Stem Cell Rep. 2017;9(6):1839–52.
   PubMed Web of Science ®Google Scholar
• Harrison IF, Powell NM, Dexter DT. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease. J Neurochem. 2019;148(1):136–156.
   PubMed Web of Science ®Google Scholar
• Jia H, Li X, Gao H, Feng Z, Li X, Zhao L, et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease. J Neurosci Res. 2008;86(9):2083–90.
   PubMed Web of Science ®Google Scholar
• Alisky JM. Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash–a case report. Nutr Neurosci. 2005;8(5–6):327–9.
   PubMed Web of Science ®Google Scholar
• Bender DA, Earl CJ, Lees AJ. Niacin depletion in parkinsonian patients treated with L-dopa, benserazide and carbidopa. Clin Sci (Lond). 1979;56(1):89–93.
   PubMed Web of Science ®Google Scholar
• Chiang PW, Wang J, Chen Y, Fu Q, Zhong J, Chen Y, et al. Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet. 2012;44(9):972–4.
   PubMed Web of Science ®Google Scholar
• Falk MJ, Zhang Q, Nakamaru-Ogiso E, Kannabiran C, Fonseca-Kelly Z, Chakarova C, et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet. 2012;44(9):1040–5.
   PubMed Web of Science ®Google Scholar
• Koenekoop RK, Wang H, Majewski J, Wang X, Lopez I, Ren H, et al. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet. 2012;44(9):1035–9.
   PubMed Web of Science ®Google Scholar
• Perrault I, Hanein S, Zanlonghi X, Serre V, Nicouleau M, Defoort-Delhemmes S, et al. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat Genet. 2012;44(9):975–7.
   PubMed Web of Science ®Google Scholar
• Nash BM, Symes R, Goel H, Dinger ME, Bennetts B, Grigg JR, Jamieson RV. NMNAT1 variants cause cone and cone-rod dystrophy. Eur J Hum Genet. 2018;26(3):428–433.
   PubMed Web of Science ®Google Scholar
• Eblimit A, Zaneveld SA, Liu W, Thomas K, Wang K, Li Y, et al. NMNAT1 e257 K variant, associated with Leber congenital amaurosis (LCA9), causes a mild retinal degeneration phenotype. Exp Eye Res. 2018;173:32–43.
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Margolin Z, Borgo B, Havranek JJ, Milbrandt J. Characterization of Leber congenital amaurosis-associated NMNAT1 mutants. J Biol Chem. 2015;290(28):17228–38.
   PubMed Web of Science ®Google Scholar
• Lin JB, Kubota S, Ban N, Yoshida M, Santeford A, Sene A, et al. NAMPT-Mediated NAD(+) biosynthesis Is essential for vision In mice. Cell Rep. 2016;17(1):69–85.
   PubMed Web of Science ®Google Scholar
• Kuribayashi H, Baba Y, Iwagawa T, Arai E, Murakami A, Watanabe S. Roles of Nmnat1 in the survival of retinal progenitors through the regulation of pro-apoptotic gene expression via histone acetylation. Cell Death Dis. 2018;9(9):891.
   PubMedGoogle Scholar
• Nickells RW, Howell GR, Soto I, John SW. Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu Rev Neurosci. 2012;35:153–79.
   PubMed Web of Science ®Google Scholar
• Howell GR, Libby RT, Jakobs TC, Smith RS, Phalan FC, Barter JW, et al. Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol. 2007;179(7):1523–37.
   PubMed Web of Science ®Google Scholar
• Beirowski B, Babetto E, Coleman MP, Martin KR. The WldS gene delays axonal but not somatic degeneration in a rat glaucoma model. Eur J Neurosci. 2008;28(6):1166–79.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhang L, Sasaki Y, Milbrandt J, Gidday JM. Protection of mouse retinal ganglion cell axons and soma from glaucomatous and ischemic injury by cytoplasmic overexpression of Nmnat1. Invest Ophthalmol Vis Sci. 2013;54(1):25–36.
   PubMed Web of Science ®Google Scholar
• Kitaoka Y, Munemasa Y, Kojima K, Hirano A, Ueno S, Takagi H. Axonal protection by Nmnat3 overexpression with involvement of autophagy in optic nerve degeneration. Cell Death Dis. 2013;4:e860.
   PubMed Web of Science ®Google Scholar
• Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355(6326):756–60.
   PubMed Web of Science ®Google Scholar
• Williams PA, Harder JM, Foxworth NE, Cardozo BH, Cochran KE, John SWM. Nicotinamide and WLD(S) act together to prevent neurodegeneration in glaucoma. Front Neurosci. 2017;11:232.
   PubMed Web of Science ®Google Scholar
• Ryu D, Zhang H, Ropelle ER, Sorrentino V, Mazala DA, Mouchiroud L, et al. NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation. Sci Transl Med. 2016;8(361):361ra139.
   PubMed Web of Science ®Google Scholar
• Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsstrom S, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med. 2014;6(6):721–31.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, et al. NAD(+) repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436–43.
   PubMed Web of Science ®Google Scholar
• Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, et al. Long-term administration of nicotinamide mononucleotide mitigates Age-associated physiological decline in mice. Cell Metab. 2016;24(6):795–806.
   PubMed Web of Science ®Google Scholar
• Trammell SA, Yu L, Redpath P, Migaud ME, Brenner C. Nicotinamide riboside is a major NAD+ precursor vitamin in Cow milk. J Nutr. 2016;146(5):957–63.
   PubMed Web of Science ®Google Scholar
• Ummarino S, Mozzon M, Zamporlini F, Amici A, Mazzola F, Orsomando G, et al. Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay. Food Chem. 2017;221:161–8.
   PubMed Web of Science ®Google Scholar
• Redeuil K, Vulcano J, Prencipe FP, Benet S, Campos-Gimenez E, Meschiari M. First quantification of nicotinamide riboside with B3 vitamers and coenzymes secreted in human milk by liquid chromatography-tandem-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1110–1111:74–80.
   PubMed Web of Science ®Google Scholar
• Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54(2):558–9.
   PubMed Web of Science ®Google Scholar
• European Nicotinamide Diabetes Intervention Trial G. Intervening before the onset of type 1 diabetes: baseline data from the European nicotinamide diabetes intervention trial (ENDIT). Diabetologia. 2003;46(3):339–46.
   PubMed Web of Science ®Google Scholar
• Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.
   PubMed Web of Science ®Google Scholar
• Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017;12(12):e0186459.
   PubMed Web of Science ®Google Scholar
• Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
   PubMedGoogle Scholar
• Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343–353.
   PubMed Web of Science ®Google Scholar
• Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017;3:17.
   PubMed Web of Science ®Google Scholar
• Tsubota K. The first human clinical study for NMN has started in Japan. NPJ Aging Mech Dis. 2016;2:16021.
   PubMed Web of Science ®Google Scholar
• Deloux R, Tannous C, Ferry A, Li Z, Mericskay M. Aged nicotinamide riboside kinase 2 deficient mice present an altered response to endurance exercise training. Front Physiol. 2018;9:1290.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Hikosaka K, Mahmood A, Tobe K, Shojaku H, Inohara H, Nakagawa T. Nmnat3 Is dispensable in mitochondrial NAD level maintenance In vivo. PLoS One. 2016;11(1):e0147037.
   PubMed Web of Science ®Google Scholar
• Davila A, Liu L, Chellappa K, Redpath P, Nakamaru-Ogiso E, Paolella LM, et al. Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. Elife. 2018;7:e33246.
   PubMed Web of Science ®Google Scholar
• Grozio A, Mills KF, Yoshino J, Bruzzone S, Sociali G, Tokizane K, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47–57.
   PubMedGoogle Scholar
• Nikiforov A, Dolle C, Niere M, Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem. 2011;286(24):21767–78.
   PubMed Web of Science ®Google Scholar
• Lu SP, Lin SJ. Phosphate-responsive signaling pathway is a novel component of NAD+ metabolism in saccharomyces cerevisiae. J Biol Chem. 2011;286(16):14271–81.
   PubMed Web of Science ®Google Scholar
• Guest J, Grant R, Mori TA, and Croft KD. Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid. PLoS One. 2014;9(1):e85335.
   PubMed Web of Science ®Google Scholar
• Chaleckis R, Murakami I, Takada J, Kondoh H, and Yanagida M. Individual variability in human blood metabolites identifies age-related differences. Proc Natl Acad Sci U S A. 2016;113(16):4252–9.
   PubMed Web of Science ®Google Scholar
• Conforti L, Janeckova L, Wagner D, Mazzola F, Cialabrini L, Di Stefano M, et al., Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration. FEBS J. 2011;278(15):2666–79.
   PubMed Web of Science ®Google Scholar
• Hicks AN, Lorenzetti D, Gilley J, Lu B, Andersson KE, Miligan C, et al., Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo. PLoS One. 2012;7(10):e47869.
   PubMed Web of Science ®Google Scholar